Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC

NCT07646639 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

122

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer
Radiotherapy

Interventions

DRUG: Sintilimab + IL-2 Combined with CAPOX
RADIATION: Short-course low-dose radiotherapy
RADIATION: Short-course standard-dose radiotherapy

Sponsor

The First Affiliated Hospital with Nanjing Medical University